A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [11C]altropane and [11C] raclopride

Biological Psychiatry

Volumn 68, Issue 10, 2010, Pages 964-970

  Spencer, Thomas J ^a,b   Madras, Bertha K ^b   Bonab, Ali A ^a,b,c   Dougherty, Darin D ^a,b   Clarke, Allison ^a   Mirto, Tara ^a   Martin, Jessica ^a   Fischman, Alan J ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

ADHD; neurochemical imaging; PET imaging; pharmacokinetics; stimulants; substance abuse

Indexed keywords

ALTROPANE; ALTROPANE C 11; ARMODAFINIL; BRAIN PROTEIN; CARBON 11; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; EXTRACELLULAR DOPAMINE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; WAKEFULNESS;

ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; CARBON RADIOISOTOPES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOLIGAND ASSAY;

EID: 78049427180     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.08.026     Document Type: Article

References (25)

1. M.J. Minzenberg, and C.S. Carter Modafinil: A review of neurochemical actions and effects on cognition Neuropsychopharmacology 33 2008 1477 1502
2. E. Mignot, S. Nishino, C. Guilleminault, and W.C. Dement Modafinil binds to the dopamine uptake carrier site with low affinity Sleep 17 1994 436 437
3. D.R. Jasinski An evaluation of the abuse potential of modafinil using methylphenidate as a reference J Psychopharmacol 14 2000 53 60
4. J. Biederman, J.M. Swanson, S.B. Wigal, C.J. Kratochvil, S.W. Boellner, and C.Q. Earl Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study Pediatrics 116 2005 e777 e784
5. J.M. Swanson, L.L. Greenhill, F.A. Lopez, A. Sedillo, C.Q. Earl, J.G. Jiang, and J. Biederman Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation J Clin Psychiatry 67 2006 137 147
6. J. Biederman, J.M. Swanson, S.B. Wigal, S.W. Boellner, C.Q. Earl, and F.A. Lopez A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: A randomized, double-blind, and placebo-controlled study J Clin Psychiatry 67 2006 727 735
7. A.J. Fischman, A.A. Bonab, J.W. Babich, N.M. Alpert, S.L. Rauch, and D.R. Elmaleh Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone J Pharmacol Exp Ther 279 1996 939 947
8. A.J. Fischman, N.M. Alpert, and R.H. Rubin Pharmacokinetic imaging: A noninvasive method for determining drug distribution and action Clin Pharmacokinet 41 2002 581 602
9. D.E. Salazar, and A.J. Fischman Central nervous system pharmacokinetics of psychiatric drugs J Clin Pharmacol Suppl 1999 10S 12S
10. A.J. Fischman, N.M. Alpert, J.W. Babich, and R.H. Rubin The role of positron emission tomography in pharmacokinetic analysis Drug Metab Rev 29 1997 923 956
11. B.T. Christian, E. Livni, J.W. Babich, N.M. Alpert, D.D. Dischino, and E. Ruediger Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography J Pharmacol Exp Ther 279 1996 325 331
12. T.J. Spencer, J. Biederman, P.E. Ciccone, B.K. Madras, D.D. Dougherty, and A.A. Bonab PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate Am J Psychiatry 163 2006 387 395
13. N.D. Volkow, J.S. Fowler, J. Logan, D. Alexoff, W. Zhu, and F. Telang Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications JAMA 301 2009 1148 1154
14. B.K. Madras, Z. Xie, Z. Lin, A. Jassen, H. Panas, and L. Lynch Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro J Pharmacol Exp Ther 319 2006 561 569
15. A.J. Fischman, A.A. Bonab, J.W. Babich, E. Livni, N.M. Alpert, P.C. Meltzer, and B.K. Madras [(11)C, (127)I] Altropane: A highly selective ligand for PET imaging of dopamine transporter sites Synapse 39 2001 332 342
16. M. Darwish, M. Kirby, E.T. Hellriegel, R. Yang, and P. Robertson Jr Pharmacokinetic profile of armodafinil in healthy subjects: Pooled analysis of data from three randomized studies Clin Drug Investig 29 2009 87 100
17. N. Volkow, G. Wang, J. Fowler, S. Gatley, J. Logan, and Y. Ding Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate Am J Psychiatry 155 1998 1325 1331
18. N.D. Volkow, G.J. Wang, J.S. Fowler, J. Logan, M. Jayne, and D. Franceschi "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect Synapse 44 2002 175 180
19. N.D. Volkow, G. Wang, J.S. Fowler, J. Logan, M. Gerasimov, and L. Maynard Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain J Neurosci 21 2001 RC121
20. N.D. Volkow, G.J. Wang, J.S. Fowler, J. Logan, D. Franceschi, and L. Maynard Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications Synapse 43 2002 181 187
21. W.M. Qu, Z.L. Huang, X.H. Xu, N. Matsumoto, and Y. Urade Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil J Neurosci 28 2008 8462 8469
22. D. Zolkowska, R. Jain, R.B. Rothman, J.S. Partilla, B.L. Roth, and V. Setola Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil J Pharmacol Exp Ther 329 2009 738 746
23. J.P. Wisor, and K.S. Eriksson Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil Neuroscience 132 2005 1027 1034
24. B.K. Madras, L.M. Gracz, M.A. Fahey, D. Elmaleh, P.C. Meltzer, and A.Y. Liang Altropane, a SPECT or PET imaging probe for dopamine neurons III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain Synapse 29 1998 116 127
25. C.H. Lammers, U. D'Souza, Z.H. Qin, S.H. Lee, S. Yajima, and M.M. Mouradian Regulation of striatal dopamine receptors by estrogen Synapse 34 1999 222 227